Device Trial Radar · NCT04542616
Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma
Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Aug 13, 2020
Primary completion
Jul 31, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- State University of New York at BuffaloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.
Conditions
- Glaucoma
Interventions
Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantationDevice
Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP)Time frame: Baseline, Month 1, Month 3, Month 6, Month 12, Month 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Ira G. Ross Eye Institute
Buffalo, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.